Patents by Inventor Brian Sherer

Brian Sherer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20230303514
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: March 6, 2023
    Publication date: September 28, 2023
    Inventors: Brian A. Sherer, Nadia Brugger
  • TLR7/8 antagonists and uses thereof
    Patent number: 11629134
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Grant
    Filed: December 19, 2020
    Date of Patent: April 18, 2023
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger
  • PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
    Publication number: 20230019491
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Application
    Filed: October 17, 2018
    Publication date: January 19, 2023
    Inventors: Srinivasa R. Karra, Yufang XIAO, Brian Sherer
  • TLR7/8 antagonists and uses thereof
    Patent number: 11512069
    Abstract: A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I-e or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: November 29, 2022
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • Pyrimidine TBK/IKKe inhibitor compounds and uses thereof
    Patent number: 11440899
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: September 13, 2022
    Assignee: Merck Patent GmbH
    Inventors: Srinivasa R. Karra, Yufang Xiao, Brian Sherer, Eugene Checkler
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210300940
    Abstract: Compounds of Formula (I) and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: July 29, 2019
    Publication date: September 30, 2021
    Applicant: Merck Patent GmbH
    Inventors: Brian Sherer, Ruoxi Lan, Nadia Brugger, Xiaoling Chen, Momar Toure, Esther Cleary, Lizbeth Celeste Deselm, Yanping Wang
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 11098041
    Abstract: Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: August 24, 2021
    Assignee: Merck Patent GmbH
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
    Publication number: 20210214339
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Application
    Filed: October 17, 2018
    Publication date: July 15, 2021
    Inventors: Srinivasa R. KARRA, Yufang XIAO, Brian SHERER, Eugene CHECKLER
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210115013
    Abstract: Compounds of Formula I and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: December 19, 2020
    Publication date: April 22, 2021
    Inventors: Brian A. SHERER, Nadia Brugger
  • TLR7/8 antagonists and uses thereof
    Patent number: 10947213
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: March 16, 2021
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger
  • TLR7/8 antagonists and uses thereof
    Patent number: 10947214
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: March 16, 2021
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210002255
    Abstract: A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 7, 2021
    Inventors: Brian A. SHERER, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210002256
    Abstract: A compound of Formula I or pharmaceutically acceptable compositions thereof, is useful to as a TLR7/8 antagonist.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 7, 2021
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND IDO1 INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20210002371
    Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises an anti-PD-L1 antibody and an IDO1 inhibitor. The therapeutic combination is particularly intended for use in treating a subject having a cancer that tests positive for PD-L1 or IDO1 expression.
    Type: Application
    Filed: December 19, 2018
    Publication date: January 7, 2021
    Inventors: Brian A. SHERER, Claude GIMMI, Jacques MOISAN
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20200369648
    Abstract: Compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists, are described herein.
    Type: Application
    Filed: August 13, 2020
    Publication date: November 26, 2020
    Inventors: Brian A. Sherer, Nadia Brugger, Ruoxi Lan, Xiaoling Chen
  • TLR7/8 antagonists and uses thereof
    Patent number: 10836750
    Abstract: Compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists, are described herein.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: November 17, 2020
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger, Ruoxi Lan, Xiaoling Chen
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20200316051
    Abstract: A treatment of disorders related to TLR7/8 overexpression or aberrant activation is provided. The disorder may include multiple sclerosis, Alzheimer's Disease, myositis, stroke, ischemia, CNS neuropathies, systemic lupus erythematosus, lupus nephritis, Sjogren's syndrome, Guillain-Barré syndrome, alcoholic hepatitis, non-alcoholic steatohepatitis, congenital heart block, autoimmune hepatitis, autoimmune pancreatitis, adult onset Still's disease, drug-induced neurological disorders, and substance addiction. A compound of Formula (I) is useful to treat such disorders.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 8, 2020
    Inventors: Brian A. Sherer, Jaromir Vlach
  • TLR7/8 antagonists and uses thereof
    Patent number: 10793553
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 6, 2020
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger, Ruoxi Lan, Xiaoling Chen
  • TLR7/8 antagonists and uses thereof
    Patent number: 10696649
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: June 30, 2020
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20200095222
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: November 26, 2019
    Publication date: March 26, 2020
    Inventors: Brian A. SHERER, Nadia Brugger